For 25 years, Morunda has been interviewing leaders in Japan’s pharmaceutical and medical device industry. Most country managers typically come from a commercial background, rooted in sales and marketing. It’s rare to find country managers who come from finance or…
HOME > REGULATORY
REGULATORY
- LDP Pharma Study Group to Draw Up Resolution in May before Honebuto Paper
April 13, 2023
- Lawmakers Split 50/50 on Abortion Pill, No Conclusion at LDP Panel
April 13, 2023
- Ultomiris’ NMOSD Nod Up for Advisory Panel Review on April 26
April 13, 2023
- Mpox Cases Top 100 in Japan, 10 New Patients Confirmed
April 13, 2023
- Pandemic Response Agency to Be Set Up as Early as September: Minister Goto
April 12, 2023
- Japan Aims to Cut Use of IV Carbapenem Antibiotics by 20%: AMR Action Plan
April 11, 2023
- LDP Project Team Calls for Price Maintenance During Patent Period and Rethink of Off-Year Cuts
April 11, 2023
- Skyrizi’s Palmoplantar Pustulosis Use on PAFSC Agenda on April 24
April 11, 2023
- China Envoy Says Spying Allegations of Astellas Employee Becoming Certain
April 10, 2023
- 9-Valent HPV Vaccine Program Poses Opportunity to Boost Inoculation Rate: LDP Lawmaker
April 7, 2023
- Japan Needs Guidelines on Conditional Approval for Regenerative Medicines: Lawmakers
April 7, 2023
- Tokyo Likely to See Next COVID Spike around First Half of May: Experts
April 7, 2023
- MHLW to Make Case-by-Case Decisions on Use of “Specified Clinical Research” Data in Regulatory Filings
April 6, 2023
- Expert Panel Questions Requirement for Generic Listing in All Versions
April 5, 2023
- Expert Panel Mixed on Macroeconomic Indexing of Drug Cost; Govt Urged to Quit Targeting Pharma for Savings
April 5, 2023
- Japanese Embassy Official Meets Astellas Employee Detained in China
April 5, 2023
- Antibiotics against CRE Chosen for Japan’s Revenue-Guarantee Pilot Project
April 5, 2023
- Health Minister Vows Transparency in Vaccine Purchase after Audit Report
April 4, 2023
- MHLW Issues Guidance on eConsent in Clinical Trials
April 4, 2023
- Japanese Foreign Minister Demands Release of Man Detained in China
April 3, 2023
ページ
Earlier this month, the Ministry of Finance (MOF) unveiled a long list of social security proposals towards the FY2025 budgeting,…
A Japanese health ministry panel discussing the generic industry structure on May 22 put together a report in which it…
A Japanese health ministry study group focused on pharmaceutical regulations on March 21 agreed on a policy to encourage the…
The Japanese health ministry on December 22 approved a batch of medicines for additional indications, including Otsuka Pharmaceutical’s atypical antipsychotic Rexulti (brexpiprazole) and Zenyaku Kogyo’s anti-CD20 antibody Rituxan (rituximab).Rexulti is now newly indicated for the treatment of depression and depressive…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…
The Japanese health ministry’s expert panel tasked to discuss comprehensive policies for the rapid and stable supply of pharmaceuticals generally…
A key Japanese reimbursement policy panel on December 16 approved the government-backed plan for the FY2023 “off-year” drug price revision.…
Authorized generic (AG) strategies taken by innovative drug makers might help soften the impact of generic competition in their businesses but such tactics might also accelerate the application of “G1”/“G2” price cuts for their off-patent brand-name medicines, a Jiho tally…
Japan’s health ministry announced new NHI prices to be applied in April under the FY2022 drug price revision in the official gazette on March 4, with the earlier application of so-called “G1” price cuts to be implemented for the first…